Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Liaoning Cancer Hospital & Institute500 enrolled

Overview

A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

inetetamabDRUG

8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. An age of at least 18 years or older 2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer 3. Having at least one measurable lesion as defined 4. Receiving inetetamab-based therapy in the recurrent or metastatic stage 5. Having traceable medical history records Exclusion Criteria: 1. Pregnant or lactating women 2. Patients with other conditions deemed unsuitable for participating in this study by the researcher

Locations (1)

Liaoning Cancer Hospital &Institue

Shenyang, China

Outcomes

Primary Outcomes

Progression Free Survival(PFS)

Time frame: 12 months

Secondary Outcomes

objective response rate (ORR)

Time frame: 12 months

Adverse events (AEs)

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.